FIELD: biotechnologies.
SUBSTANCE: population of Tr1 cells is identified, being aimed against food antigen from regular ration of a human being and having phenotype CD4+CD25-FoxP3- in idle condition. The produced population of Tr1 cells in a combination with one or several pharmaceutically acceptable carriers, or in a combination with one or more pharmaceutical agents, used to treat inflammatory bowel conditions and selected from a group including anti-TNF, natalizumab, anti-IL1, anti-IL-6, anti-IL-12, anti-IL-17 and anti-IL-23, analogues of antagonist of a receptor IL-1.5 aminosalicylic acid and its analogues, corticoids, probiotics, methotrexate, azathioprine, 6-mercaptopurine, thalidomide, leflunomide, used within pharmaceutical compositions for treatment of inflammatory bowel conditions.
EFFECT: invention makes it possible to produce an efficient agent for treatment of inflammatory bowel conditions.
15 cl, 8 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| Tr1 CELLS, MESENCHYMAL STEM CELLS AND USING THEM | 2008 |
|
RU2493869C2 |
| COMPOSITIONS FOR TREATMENT OF DISSEMINATED SCLEROSIS | 2008 |
|
RU2492234C2 |
| METHODS FOR IDENTIFICATION, SELECTION, ENRICHMENT AND DEPLETION OF Tr1 CELLS POPULATIONS, Tr1 CELLS POPULATIONS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR THERAPY EFFECT MONITORING | 2011 |
|
RU2627445C2 |
| COMPOSITION FOR TREATING ARTHRITIS | 2009 |
|
RU2563360C2 |
| PROBIOTIC STRAIN OF Bifidobacterium longum, COMPOSITION CONTAINING SUCH STRAIN AND USE THEREOF | 2008 |
|
RU2473681C2 |
| PLANCH AND INFLAMMATION | 2008 |
|
RU2499604C2 |
| MUCOSAL INDUCTION OF ANTIGEN TOLERANCE | 2006 |
|
RU2420569C2 |
| ALLERGIC SENSITISATION PREVENTION | 2008 |
|
RU2429881C2 |
| MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING | 2008 |
|
RU2504552C2 |
| SOLUBLE MEDIATOR | 2012 |
|
RU2660580C2 |
